In 2014, the HIV Vaccines and Microbicides Resource Tracking Working Group and AVAC began a collaboration with the International AIDS Society’s (IAS) Towards an HIV Cure initiative. AVAC, Treatment Action Group (TAG) and the IAS brought together a group to review and allocate grants towards HIV cure research and analyze data on global funding. The working group released a report in July 2021, Global Investment in HIV Cure Research and Development in 2020.
Global Investment in HIV Cure Research and Development in 2020
Future Prospects for New Vaccines Against Sexually Transmitted Infections
This review provides an update on the need, development status, and important next steps for advancing development of vaccines against sexually transmitted infections (STIs), including herpes simplex virus (HSV), Neisseria gonorrhoeae (gonorrhea), Chlamydia trachomatis (chlamydia), and Treponema pallidum (syphilis).
PEPFAR-Funded PrEP and VMMC Services in 14 Priority Countries
This infographic shows that PEPFAR’s increased investment and creation of a budget code resulted in improved scale-up of VMMC (VMMC). A budget code could have the same impact if applied to PrEP initiations.
HIV Vaccines: The basics
This introductory PowerPoint slide set reviews basic concepts, and provides an overview of research status and recent developments.
Ethical considerations in HIV prevention trials
UNAIDS and the World Health Organization have published this updated guidance on ethical considerations in HIV prevention trials. The new guidance is the result of a year-long process that saw more than 80 experts and members of the public give inputs and is published 21 years after the first edition appeared.
Broadly Neutralizing Antibody Combinations
Overview of the combinations of broadly neutralizing antibodies (bNAbs) under investigation in early clinical studies for HIV prevention.
Biomedical HIV Prevention Trials: Results, milestones and more
This graphic shows the updated status of large-scale prevention trials through 2022 and the impact of COVID-19 on each trial.
Another version of this graphic is available here (same content, different visual Treatment U=U).
Designing a New Generation of HIV Prevention Efficacy Trials
Designing trials to test new HIV prevention modalities remains crucial; high rates of new infections persist in communities all over the world. Even with effective tools becoming more accessible, it’s clear no single option fits every need. But those same options make the design of future trials increasingly complex. Bill Snow, AVAC co-founder and senior advisor, explores this issue in Designing a New Generation of Prevention Efficacy Trials. The report lays out basic concepts in innovations in trial design and an analysis of the implications for advocacy.
A Statement on the Future of HIV Prevention Trials
AVAC’s inaugural Trial Design Academy convened in September 2019. At that meeting, a group of around 20 HIV prevention advocates from across the globe explored technical issues related to trial designs, and engaged with researchers, statisticians and regulators to understand the decisions—which must incorporate input from advocates. As an outcome of this workshop, the group developed a statement of its viewpoints and stances on this new, complex generation of HIV prevention trials—this work was presented at AIDS 2020 Virtual: Advocates’ Perspectives on Next-Generation HIV Prevention Trial Design. Read the consensus statement.
COVID-19 Vaccine Pipeline Snapshot
A snapshot of the COVID-19 vaccine pipeline. Excerpted from Five “P”s to Watch.